Intrathecal insulin-like growth factor 1 but not insulin enhances myelin repair in young and aged rats
- 1 May 2017
- journal article
- Published by Elsevier in Neuroscience Letters
- Vol. 648, 41-46
Abstract
No abstract availableKeywords
Funding Information
- Swiss MS Society
- Hartmann-Müller Foundation
- Desirée-and-Niels-Yde Foundation
- Swiss National Science Foundation (323530_151488)
This publication has 29 references indexed in Scilit:
- Immunopathology of multiple sclerosisNature Reviews Immunology, 2015
- Intrathecal Rituximab Therapy in Multiple Sclerosis: Review of Evidence Supporting the Need for Future TrialsCurrent Drug Targets, 2014
- Insulin‐like growth factor‐1 stimulates regulatory T cells and suppresses autoimmune diseaseEMBO Molecular Medicine, 2014
- Targeting Insulin-Like Growth Factor 1 Leads to Amelioration of Inflammatory Demyelinating DiseasePLOS ONE, 2014
- The Insulin‐like Growth Factor System in Multiple Sclerosis2007
- Enhancing Central Nervous System Remyelination in Multiple SclerosisNeuron, 2005
- Adiposity signals and food reward: expanding the CNS roles of insulin and leptinAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2003
- Insulin-Like Growth Factor-1 Fails to Enhance Central Nervous System Myelin Repair during Autoimmune DemyelinationThe American Journal of Pathology, 2000
- Rat insulin turnover in vivo.Endocrinology, 1995
- Reduction of food intake and body weight by chronic intraventricular insulin infusionBrain Research Bulletin, 1984